JP5622720B2 - 神経原繊維変化に関連する進行性認知障害の治療方法 - Google Patents

神経原繊維変化に関連する進行性認知障害の治療方法 Download PDF

Info

Publication number
JP5622720B2
JP5622720B2 JP2011510712A JP2011510712A JP5622720B2 JP 5622720 B2 JP5622720 B2 JP 5622720B2 JP 2011510712 A JP2011510712 A JP 2011510712A JP 2011510712 A JP2011510712 A JP 2011510712A JP 5622720 B2 JP5622720 B2 JP 5622720B2
Authority
JP
Japan
Prior art keywords
leptin
agents
acid
tau
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011510712A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011520981A5 (enExample
JP2011520981A (ja
Inventor
ニコラオス テザプシディス
ニコラオス テザプシディス
グレコスティーヴン
スティーヴン グレコ
マーク スミス
マーク スミス
Original Assignee
ニューロテスインコーポレイテッド
ニューロテス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューロテスインコーポレイテッド, ニューロテス インコーポレイテッド filed Critical ニューロテスインコーポレイテッド
Publication of JP2011520981A publication Critical patent/JP2011520981A/ja
Publication of JP2011520981A5 publication Critical patent/JP2011520981A5/ja
Application granted granted Critical
Publication of JP5622720B2 publication Critical patent/JP5622720B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2011510712A 2008-05-21 2009-05-21 神経原繊維変化に関連する進行性認知障害の治療方法 Active JP5622720B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5500908P 2008-05-21 2008-05-21
US61/055,009 2008-05-21
PCT/US2009/044907 WO2009143380A2 (en) 2008-05-21 2009-05-21 Methods for treating progressive cognitive disorders related to neurofibrillary tangles

Publications (3)

Publication Number Publication Date
JP2011520981A JP2011520981A (ja) 2011-07-21
JP2011520981A5 JP2011520981A5 (enExample) 2012-07-05
JP5622720B2 true JP5622720B2 (ja) 2014-11-12

Family

ID=41340901

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011510712A Active JP5622720B2 (ja) 2008-05-21 2009-05-21 神経原繊維変化に関連する進行性認知障害の治療方法

Country Status (9)

Country Link
US (2) US8642543B2 (enExample)
EP (1) EP2326339A4 (enExample)
JP (1) JP5622720B2 (enExample)
KR (1) KR20110028457A (enExample)
CN (1) CN102099048A (enExample)
AU (1) AU2009248914A1 (enExample)
CA (1) CA2725143A1 (enExample)
WO (1) WO2009143380A2 (enExample)
ZA (1) ZA201008303B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481043B2 (en) * 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
KR20110028457A (ko) * 2008-05-21 2011-03-18 뉴로테즈 인코포레이티드 신경섬유 매듭과 연관된 신경변성 장애를 치료하는 방법
CA2742600A1 (en) 2008-11-04 2010-05-14 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
EP3620154A1 (en) * 2009-02-06 2020-03-11 University Of Southern California Therapeutic compositions comprising monoterpenes
CN104744215B (zh) 2010-03-03 2019-03-15 尼昂克技术公司 包含单萜的药物组合物
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
US9499461B2 (en) 2010-08-27 2016-11-22 Neonc Technologies, Inc. Pharmaceutical compositions comprising POH derivatives
ES3056006T3 (en) 2010-12-17 2026-02-17 Univ Southern California Methods and devices for using isoperillyl alcohol
US20140088000A1 (en) * 2012-09-27 2014-03-27 Neurotez, Inc. Leptin Rescues Neurons from Alzheimer's Disease Related Pathways Triggered by Lipid Burden
WO2014165043A1 (en) * 2013-03-13 2014-10-09 Neurotez, Inc. Fragments, mutants and chimeric fusion proteins of leptin for treating alzheimer's disease
WO2016130800A2 (en) 2015-02-12 2016-08-18 Neonc Technologies Inc. Pharmaceutical compositions comprising perillyl alcohol derivatives
CN110267538B (zh) 2016-11-30 2022-04-19 尼昂克技术公司 紫苏醇-3-溴丙酮酸缀合物和治疗癌症的方法
JP7325425B2 (ja) 2018-02-08 2023-08-14 ネオンク テクノロジーズ インク． 血液脳関門を透過性にする方法
WO2020182322A1 (en) 2019-03-14 2020-09-17 Om Pharma Sa Method of treating and/or preventing asthma, asthma exacerbations, allergic asthma and/or associated conditions with microbiota related to respiratory disorders
AU2021211012A1 (en) 2020-01-24 2022-08-25 Aim Immunotech Inc. Methods, compositions, and vaccines for treating a virus infection
CN114958760B (zh) * 2021-02-23 2024-04-26 南京启真基因工程有限公司 一种构建阿尔兹海默症模型猪的基因编辑技术及其应用

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
DK172541B1 (da) 1982-10-08 1998-12-07 Glaxo Group Ltd Apparat til administrering af medikamenter til patienter og en medikamentpakning til brug i apparatet
AU591152B2 (en) 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6048837A (en) 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US20020107211A1 (en) 1995-06-07 2002-08-08 The Rockefeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
JPH11501297A (ja) 1995-01-31 1999-02-02 イーライ・リリー・アンド・カンパニー 抗肥満症タンパク質
US5559208A (en) 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
US5554727A (en) 1995-01-31 1996-09-10 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
EP0725079A1 (en) 1995-01-31 1996-08-07 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5605886A (en) 1995-01-31 1997-02-25 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US6068976A (en) 1995-03-20 2000-05-30 Ligand Pharmaceuticals Incorporated Modulators of ob gene and screening methods therefor
ES2093593T1 (es) 1995-05-05 1997-01-01 Hoffmann La Roche Proteinas obesas (ob) recombinantes.
AU695934B2 (en) 1995-06-30 1998-08-27 Eli Lilly And Company Methods for treating diabetes
US5698389A (en) 1995-11-16 1997-12-16 Tularik, Inc. Transcriptional promoter of the murine obesity gene
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
IL124831A0 (en) 1995-12-27 1999-01-26 Genentech Inc Ob protein derivatives having prolonged half-life
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US6025324A (en) 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
US5830450A (en) 1996-06-19 1998-11-03 Lallone; Roger L. Compositions of leptin bound to an apolipoprotein
US6630346B1 (en) 1996-06-20 2003-10-07 Merck & Co., Inc. Gene therapy for obesity
US6001816A (en) 1996-06-20 1999-12-14 Merck & Co., Inc. Gene therapy for leptin deficiency
EP0921820A4 (en) 1996-06-20 2003-01-15 Merck & Co Inc GENETERAPY FOR OBESITY
JP2002514904A (ja) 1996-06-20 2002-05-21 メルク エンド カンパニー インコーポレーテッド 肥満に対する遺伝子治療
US20060205660A1 (en) 1996-06-20 2006-09-14 Sauvage Frederic D OB protein-immunoglobulin chimeras
AU5654998A (en) 1996-12-06 1998-06-29 F. Hoffmann-La Roche Ag Muteins of obese protein
US20020019352A1 (en) 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
IL132380A0 (en) 1997-04-17 2001-03-19 Amgen Inc Compositions comprising conjugates of stable active human ob protein with antibody fc chain and methods
US6020004A (en) 1997-04-17 2000-02-01 Amgen Inc. Biodegradable microparticles for the sustained delivery of therapeutic drugs
IL120733A0 (en) 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
EP0950417A3 (en) 1998-02-23 2000-02-23 Pfizer Products Inc. Treatment of skeletal disorders
JP4215857B2 (ja) * 1998-03-26 2009-01-28 裕 大村 学習・記憶能力改善剤
GB9807062D0 (en) 1998-04-02 1998-06-03 Imp College Innovations Ltd Immune response
CA2335107C (en) 1998-07-28 2010-01-19 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Leptin-mediated gene-induction
CA2337667C (en) 1998-08-10 2008-04-29 Amgen Inc. Dextran-leptin conjugates, pharmaceutical compositions and related methods
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
CA2344623A1 (en) 1998-10-02 2000-04-13 Amgen Inc. Method to determine a predisposition to leptin treatment
US6716810B1 (en) 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
MXPA01005818A (es) 1998-12-09 2003-07-21 Eleanor Rooseveltl Inst Composicion y metodo para la regulacion del peso del cuerpo y condiciones asociadas.
MXPA01006922A (es) 1999-01-07 2002-04-24 Lexigen Pharm Corp Expresion y exportacion de proteinas de anti-obesidad como proteinas de fusion en fc.
EP1151102B1 (en) 1999-02-12 2006-04-19 Amgen Inc. Glycosylated leptin compositions and related methods
US20030215423A1 (en) 1999-04-01 2003-11-20 Merck & Co., Inc. Gene therapy for obesity
US6475984B2 (en) 1999-04-29 2002-11-05 The Nemours Foundation Administration of leptin
CA2376933A1 (en) 1999-06-11 2000-12-21 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of leptin activity
AU767068B2 (en) 1999-06-11 2003-10-30 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of leptin activity
EP1210100B1 (en) * 1999-08-10 2006-06-14 UAB Research Foundation Method of treating traumatic brain using non-steroidal anti-inflammatory drugs
CA2382666A1 (en) 1999-08-23 2001-03-01 The Administrators Of The Tulane Educational Fund Modulation of the blood-brain barrier transporter for leptin
BR0107851A (pt) * 2000-01-24 2002-10-29 Innogenetics Nv Diagnose de tauopatia
US7582292B2 (en) 2000-02-26 2009-09-01 Artecel, Inc. Adipose tissue derived stromal cells for the treatment of neurological disorders
US20030049255A1 (en) * 2001-08-07 2003-03-13 Sims John E. Interleukin-1 receptors in the treatment of diseases
WO2003020303A1 (en) 2001-08-29 2003-03-13 The University Of Buckingham Use of leptin for infant with low birth weight for prevention of obesity
ATE475094T1 (de) 2001-10-22 2010-08-15 Amgen Inc Verwendung von leptin zur behandlung von lipoatrophie im menschen und verfahren zur bestimmmung einer prädisposition gegenüber der behandlung
EP2002827A2 (en) 2001-12-05 2008-12-17 The Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of sympathetic tone
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US7642281B2 (en) 2002-08-07 2010-01-05 Helicon Therapeutics, Inc. Indolone compounds useful to treat cognitive impairment
GB0323039D0 (en) * 2003-10-01 2003-11-05 Danisco Method
DE10353593A1 (de) 2003-11-17 2005-06-23 Klinikum der Universität München Großhadern-Innenstadt Leptinantagonist und Verfahren zur quantitativen Messung von Leptin
US7407929B2 (en) 2004-05-07 2008-08-05 Boston Biomedical Research Institute Leptin peptide antagonists
US20090088367A1 (en) 2004-05-10 2009-04-02 Burnham Institute For Medical Research Treatment of Insulin Resistance/Metabolic Syndrome to Alleviate the Risks of Dementia
US20050287519A1 (en) 2004-05-12 2005-12-29 Merchiers Pascal G Methods, compositions and compound assays for inhibiting amyloid-beta protein production
US7863240B2 (en) 2004-10-08 2011-01-04 Enzo Therapeutics, Inc. Methods and uses of leptin in hepatocellular carcinoma
US8043619B2 (en) 2004-10-08 2011-10-25 Yaron Ilan Methods and uses of leptin in immune modulation
US7307142B2 (en) 2004-11-26 2007-12-11 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Leptin antagonists
US7629315B2 (en) 2005-03-09 2009-12-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions for blocking the inhibitory effect of human CRP on human leptin
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
US9333240B2 (en) 2005-09-16 2016-05-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compounds for improving nutritional status, cognition and survival
EP1795895A1 (en) 2005-12-08 2007-06-13 KeyNeurotek AG A tissue-based assay system for Alzheimer-specific degeneration and pathology
US20070218504A1 (en) 2006-03-09 2007-09-20 University Of Pittsburgh Human leptin-derived polypeptides and uses thereof
WO2007139818A2 (en) 2006-05-22 2007-12-06 The Board Of Trustees Of The Leland Stanford Junior University Pharmacological treatment of cognitive impairment
WO2008048691A2 (en) 2006-10-18 2008-04-24 Amylin Pharmaceuticals, Inc. Use of leptin for treating post-lipectomy ectopic fat deposition and other post-lipectomy associated disorders
WO2008115880A2 (en) 2007-03-21 2008-09-25 The Board Of Regents Of The University Of Texas System Use of leptin for the treatment or prevention of parkinson's disease
WO2008155403A2 (en) 2007-06-20 2008-12-24 Universitat De Les Illes Balears Use of leptin in the prevention of unhealthy food habits and cardiovascular diseases
US8889622B2 (en) 2007-07-25 2014-11-18 Washington University Methods of inhibiting seizure in a subject
US20090031434A1 (en) 2007-07-26 2009-01-29 Weiping Han Animal models for obesity and neurodegenerative diseases
EP2252314B1 (en) 2008-02-27 2014-04-09 Temple University - Of The Commonwealth System of Higher Education Leptin agonist and methods of use
WO2009138762A2 (en) 2008-05-15 2009-11-19 Regen Therapeutics Plc Therapeutic use of peptides
KR20110028457A (ko) 2008-05-21 2011-03-18 뉴로테즈 인코포레이티드 신경섬유 매듭과 연관된 신경변성 장애를 치료하는 방법
CA2742600A1 (en) 2008-11-04 2010-05-14 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta

Also Published As

Publication number Publication date
US20140121157A1 (en) 2014-05-01
ZA201008303B (en) 2012-04-25
AU2009248914A1 (en) 2009-11-26
US20090291894A1 (en) 2009-11-26
CN102099048A (zh) 2011-06-15
WO2009143380A3 (en) 2010-01-14
WO2009143380A2 (en) 2009-11-26
US8642543B2 (en) 2014-02-04
CA2725143A1 (en) 2009-11-26
EP2326339A2 (en) 2011-06-01
JP2011520981A (ja) 2011-07-21
KR20110028457A (ko) 2011-03-18
EP2326339A4 (en) 2012-06-20
US20120010132A9 (en) 2012-01-12

Similar Documents

Publication Publication Date Title
JP2011520981A (ja) 神経原繊維変化に関連する進行性認知障害の治療方法
US20230285329A1 (en) Methods and Compositions for the Treatment of Steatosis-Associated Disorders
US8716220B2 (en) Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
JP2019511495A (ja) ＧＳＫ３β阻害薬チデグルシブによるＣＤＫＬ５障害の治療
JP2014530242A (ja) 皮膚疾病の処置用のケメリンｃ１５ペプチドの局所製剤
RS63866B1 (sr) Intranazalne formulacije epinefrina i postupci za lečenje bolesti
US20240000896A1 (en) Elevated intracranial pressure treatment
CN108472332A (zh) 用于通过经鼻施用来治疗中风的组合物
JP6778200B2 (ja) Ｓｐｉｒａｎｔｈｅｓ ｓｉｎｅｎｓｉｓ抽出物を含有する組成物およびその薬学的適用
JP2022514340A (ja) 過剰摂取および報酬に基づく障害を処置するための、組成物、装置、および方法
WO2006088875A2 (en) Intranasal administration of modulators of hypothalamic atp-sensitive potassium channels
WO2022125548A1 (en) Growth and differentiation factor 15 for treatment of proliferative vitreoretinopathy therapy
HK40076546B (en) Incretin for elevated intracranial pressure treatment
HK40076546A (en) Incretin for elevated intracranial pressure treatment
TWI578991B (zh) 含綬草萃取物的組合物及其醫藥應用
HK1240847B (en) Compositions containing a spiranthes sinensis extract and pharmaceutical applications thereof
EP2061497A1 (en) Compositions and methods for treatment of chronic fatigue syndrome and neurodegenerative diseases
US20170071925A1 (en) Ciclopirox for Use in Modulation of Glucose Homeostasis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120518

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130919

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131218

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140319

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140825

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140922

R150 Certificate of patent or registration of utility model

Ref document number: 5622720

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250